What happened with INCR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
InterCure serves patients who obtain cannabis for medical use, primarily through its subsidiary Canndoc. It breeds, grows and processes cannabis, and also imports supplies from overseas producers such as Organigram for conversion into Canndoc-branded products. These products include dried cannabis flowers and oils. Licensed pharmacies buy products through its distribution channels, and patients fill prescriptions at pharmacies or receive home deliveries. InterCure also operates pharmacies through subsidiaries.
Medical cannabis generates all of the company’s revenue. Almost all sales come from Israel, with a smaller business in Germany. Its southern Israeli facility has resumed production and sales following severe wartime damage, but restoration remains ongoing.
The business depends on patient demand and permission to produce and distribute cannabis. Israeli operations require medical-cannabis licenses and certifications; cross-border shipments also need export and import approvals. Further international expansion depends on meeting each market’s local rules.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
InterCure’s results hinge chiefly on Israeli medical-cannabis demand and restoring its Nir Oz facility, while Bazelet’s restructuring puts service continuity and recovery of substantial commercial balances at risk.
InterCure depends on Organigram Global Inc. for dried cannabis flower and selected varieties, turning imported supplies into Canndoc-branded medical products sold to Israeli pharmacies. Watch their supply and payment arrangements: an April 2026 settlement schedules outstanding repayments through May 2027, with earlier repayment possible in specified circumstances.
Tilray Brands, Inc. gives InterCure access to cannabis products and facilities through an exclusive strategic partnership, supporting the medical products InterCure sells to Israeli pharmacies. Tilray’s cannabis supply is the relevant business to watch for InterCure’s access to extra raw material when demand requires it.
Aurora Cannabis Inc. competes with InterCure in pharmaceutical-grade medical cannabis: both sell dried flower and extracts under strict regulatory standards, with Aurora selling directly to registered Canadian patients and InterCure supplying Israeli pharmacies. Aurora’s international medical business is worth watching for competition built on regulated production and distribution.
Canopy Growth Corporation competes with InterCure for regulated medical-cannabis sales in international markets, including Germany, where both serve medical customers. Watch Canopy’s German medical business, but keep its relevance in proportion: German end-customers accounted for 3% of InterCure’s revenue in the year ended December 31, 2025.
Village Farms International, Inc. is a competing global cannabis manufacturer named by InterCure, which sells medical-cannabis products through Israeli pharmacies. Village Farms grows cannabis through subsidiaries; its Canadian cannabis business, including Pure Sunfarms and Rose LifeScience, is the relevant business to watch rather than its produce or renewable-gas revenue.
Canopy Growth Corporation earningsCGC
Canopy Growth Corporation’s report will show how its German medical-cannabis business is faring, in a market that accounted for just 3% of InterCure’s 2025 revenue.
Read Canopy Growth’s German medical-cannabis sales alongside its results in other markets. Stronger German sales would show a more active competitor where InterCure also sells, potentially intensifying the contest for pharmacy and patient sales; weaker sales could ease that pressure, but could also signal softer demand. Since Germany accounted for only 3% of InterCure’s 2025 revenue, this is a limited competitive signal, not a verdict on InterCure’s overall business.
Organigram Global Inc. earningsOGI
Organigram Global Inc.’s report will show how its operations and finances are faring; InterCure relies on it for some cannabis inputs used in products sold to Israeli pharmacies.
Read Organigram’s cannabis operations, cash position and any disclosed repayment progress together. Steady operations and cash, with repayments progressing as disclosed, would point to a more resilient supplier; weaker operations, strained cash or delayed repayments would add uncertainty around InterCure’s access to some flower and varieties, but would not prove that deliveries had been disrupted. The conclusion is whether this part of InterCure’s supply chain looks dependable.
